1. Sino Biopharm 2025 Annual Progress in Innovative Drug Development
Sino Biopharm in2025Year Total18 Payment1 New drug class receives clinical approval for the first time, covering oncology, metabolism,Surgery/Analgesia, respiration and other fields, includingADC、PROTAC, bispecific antibodies and other cutting-edge technologies. ItsIn China,ADCDrugTQB6411（EGFR/c-MetBispecific AntibodyADC）、TQB2101（ROR1ADC）AndLM-350（CDH17 ADC) Constructed a multi-target innovation matrix;PROTACDrugTQB3019（BTKDegradant),TQB3142（Bcl-xLDegradant) andTQB3201（ARDegradation agent) cracked"Cannot"Patent Medicine"Challenge. The company has enhanced the convenience of medication through the innovation of subcutaneous injection formulations, and is simultaneously advancing in the United States andThe global clinical development in Australia and other regions reflects its innovation-driven and internationalization strategy.
2. Zong Ai Tinib Treatment HER2 Breakthrough in Mutant Non-Small Cell Lung Cancer
In 2025 Year ESMO At the Asian Conference ，Beamion LUNG-1 Study Announces Zongaitinib（Zongertinib) Treatment HER2 SuddenNon-small cell lung cancer (NSCLC) Data from Asian patients confirmedIts significant efficacy. Professor Wenfeng Fang from the Sun Yat-sen University Cancer Center pointed out,Zong Ai替尼 as a novel HER2Targeted drugs have addressed the clinical pain points of high drug resistance and limited efficacy in previous treatments. The drug has been approved. NCCNAndCSCO The guidelines recommend that the data from Asian populations further validate the consistency of efficacy across ethnicities, providingHER2Mutation NSCLC Provides a new paradigm for precise treatment and is expected to lead the exploration of future combination therapy regimens.
3. Professor Ma Jun Promotes Lymphoma AI Doctor Standard Formulation
Professor Ma Jun, Director of Harbin Hematology and Oncology Research Institute, took the lead in formulatingLymphoma Diagnosis AI Doctor's Standard, EmphasizingAI The auxiliary role needs to be clarified to ensure medical safety. The standard system covers functional boundary definition and technical specifications.Scope, Audit Mechanism, and Risk Management, Requirements AI The system has a high diagnostic accuracy rate andExplainability. Professor Ma JunPresented through clinical cases (e.g., AI (Auxiliary Discovery of Rare Causes) ShowcasedAI In the diagnosis of difficult and complicated diseases, resource optimizationThe Value in Transformation and Patient Follow-up. He called for the establishment of an inclusive AI Medical products, promoting technology to benefit the grassroots,And strengthen the combination of medical and engineering as well as talent cultivation to build a trustworthy AI Medical Diagnosis Ecosystem.
4. MindRank AI Design GLP-1 Drug EntryEntry III Phase Clinical
On December 22, MindRank announced that its AI Designed Small MoleculesGLP-1Receptor AgonistMDR-001 LaunchIII PendingClinical trials, marking the first in ChinaAI MindRank's AI-assisted drug enters confirmatory clinical stage.MDR-001 InIIbShowed excellent safety (no serious adverse events) and efficacy (24 Weekly Weight Loss10.3%），Its significant advantages lie in the improvement of cardiometabolic indicators and the reduction of transaminase. The drug was advanced toIIIPeriod,HighlightAIPharmaceutical PlatformMoleculeProThe efficiency, for China in oral small moleculesGLP-1Field Impact“Best-in-class"Provides a milestone case.
5. Kelun Botai's Lucantuzumab to be Included in Breakthrough Therapy
On December 25, Kelun Biotech's Lukansatuzumab (SKB264) Combined with PaBolizumab First-Line TreatmentPD-L1Positive Non-Small Cell Lung Cancer (NSCLC) is proposed to be included in the breakthrough therapy, which is its6 Breakthrough Therapy DesignationSet.IIIPeriodOptiTROP-Lung05 ResearchReached the primary endpoint of progression-free survival, with overall survival showing a beneficial trend, becoming the world's firstIO+ADC On the FrontlineNSCLCPositive results obtained in ChinaIIIPhase Research.The drug has been previouslyEGFRMutationNSCLCAchieved in Later-line TreatmentPFS AndOS DoubleRe-gain benefits, this timeAdvance to the front line to further consolidate its best-in-class potential in the field of lung cancer.
6. Innovent Biologics' Dual Immunotherapy Approved for Neoadjuvant Indication in Colon Cancer
December 25, Innovent Biologics' Tyvyt®(IpilimumabN01 Injection) combined with Tyvyt®(TrustDilizumab InjectionInjection) ObtainedNMPA Approval for surgically resectableIIB-IIIPeriodMSI-H/dMMRNeoadjuvant Therapy for Colon CancerTreatment, becoming the world's first and only dual immunotherapy regimen approved for this indication.IIIPeriodNeoShot-IIIResearch showsSymptomPrincipleCompleteAlleviateRate Achievement82% ，ShowAuthorDecreaseLowSurgeryAfterChemotherapyNegative担。The therapyLawFillReplenishedMSI-H/dMMR Filling the Gap in Neoadjuvant Therapy for Colon Cancer and ThroughCTLA-4AndPD-1 Dual-target Synergistic MechanismEnhance efficacy and provide new curative treatment options for patients in China.
7. Zhejiang University Sir Run Run Shaw Hospital Liver Cancer AI MindRank Ranks First in National Evaluation
Multimodal Liver Cancer Developed by Sir Run Run Shaw Hospital of Zhejiang University AI Large Model Agents in National Artificial Intelligence ApplicationsTest Base Evaluation Obtained"Intelligent Auxiliary Diagnosis "First in the Special Project. The model is based on a medical knowledge graph with tens of millions of data points andMultimodal Fusion Technology for Achieving Emergency Recognition Response Time 8.3 Seconds, Diagnostic Accuracy 84.5% RunDa HealthcareAs a partner to promote its clinical transformation, the achievement has been successfully converted into results. 2400 , and countedRowing to Kunshan and other grassroots areas
Promotion of the medical system. This agent represents“ Clinically Driven+Data Empowerment " AI Medical Integration Pathway,Provides an intelligent solution for the whole-process management of liver cancer.
8. Junshi Biosciences EGFR/HER3 Bispecific Antibody ADC Enter II Phase Clinical
Junshi Biosciences EGFR/HER3 Bispecific Antibody ADC Drug JS212 Launch II Phase clinical, becoming the second globallyThe first product of its kind to enter this phase. The study will evaluate JS212 United PD-1 Antibody TeriparatideLidunan, PD-1/VEGF Bispecific Antibody JS207 Or PD-1/IL-2 Bispecific Antibody JS213 Efficacy in advanced lung cancer, planned enrollment846 Example patient.JS212 Overcome through dual-target synergy EGFR Drug Resistance Mechanism: Preclinical Studies ShowSignificant tumor inhibition activity. Junshi Biosciences leverages multi-technology platform co-development, with the potential to enhance its effectiveness through combination strategies.Competitiveness in the field of lung cancer.
9. Enrui Kainuo CAR-NK Therapy Selected as One of the Top Ten Global Clinical Breakthroughs
Enruikainuo's Universal Type CD19 CAR-NK Therapy KN5501 Due to the treatment of systemic lupus erythematosusLupus（SLE) The breakthrough results were selected 2025 Year"Top Ten GlobalBed Breakthrough ". Published in The LancetResearch shows,18 Example Refractory SLE After the patient received treatment,6 Months with Complete Clinical Remission Rate 55.6%，And no serious adverse events. The therapy works by"Spot-type "Design to reduce costs to CAR-T One-tenth of,Achieved immune system reset and precise targeting, opening a new path for the treatment of autoimmune diseases, and received nationalHighly praised by international authoritative journals.
10. China Clinical Trials Development Report of the Past Decade
2015-2024 In ... year, the number of clinical trials in China increased. 366% ，2024 New Trial in the YearTested Globally44%, becoming a new global center for innovative drug research and development. In trials led by Chinese pharmaceutical companies, the proportion in the oncology field exceeds 50%，The first choice for overseas trials is the United States and Australia. The efficiency advantage of clinical trials in China is significant (e.g., shorter patient recruitment cycles).Short 342 Day），But need to start from"Scale Support "Towards Value-Driven" "Transformation. In the future, it is necessary to enhance the allocation of regional resources.Placement, Strengthening International Rule Synergy, and High-Quality Data Publication (16 A Study Reaches the Top Four Journals)Enhance global influence.
The reference materials are from publicly available online information, including news reports, corporate official websites, and government documents.
